Nu Skin Enterprises (NUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, at company headquarters in Provo, Utah.
Proxy materials are available online, with options for shareholders to request paper or email copies.
Shareholders are encouraged to review all proxy materials before voting.
Voting matters and shareholder proposals
Election of eight director nominees is on the agenda.
Advisory vote on executive compensation (say-on-pay) will be held.
Approval of the Amended and Restated 2024 Omnibus Incentive Plan is proposed.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is included.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and all proposals.
Director nominees include Emma S. Battle, Daniel W. Campbell, Steven J. Lund, Ryan S. Napierski, Laura Nathanson, Thomas R. Pisano, James M. Winett, Edwina D. Woodbury, and Mark A. Zorko.
Latest events from Nu Skin Enterprises
- Q2 revenue fell 17.1% year-over-year to $320.1M, with adjusted EPS at $0.20 and broad declines.NUS
Q2 2026 - Q1 2026 revenue fell 12% to $320.6M, with EPS at $0.04 and guidance maintained.NUS
Q1 2026 - Proxy covers director elections, executive pay, incentive plan, auditor ratification, and governance.NUS
Proxy filing - 2025 EPS rose 51% despite revenue declines; 2026 growth expected from new launches and India expansion.NUS
Q4 2025 - Prysm iO and digital-first expansion in emerging markets are set to drive growth and stability.NUS
28th Annual ICR Conference 2026 - Proxy covers director elections, pay, incentive plan, auditor, and ESG progress.NUS
Proxy Filing - Q3 revenue fell 13.8%–14% YOY to $430.1M; Rhyz segments grew over 20% amid core declines.NUS
Q3 2024 - Q2 revenue fell 12.2% to $439.1M, with Rhyz up 32% and a $118.3M net loss on restructuring.NUS
Q2 2024 - Q4 revenue and EPS beat guidance but fell year-over-year; 2025 outlook remains cautious.NUS
Q4 2024